Mechanism of Action
GLP-1 Receptor Signaling
Liraglutide binds GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion via cAMP/PKA pathway. Simultaneously suppresses glucagon from alpha cells during hyperglycemia. Hypothalamic GLP-1 receptors in the arcuate and paraventricular nuclei mediate appetite suppression and increased satiety signaling.
Gastric Motility and Energy Balance
Delayed gastric emptying prolongs postprandial fullness and reduces meal-associated glucose excursions. Unlike semaglutide, liraglutide's shorter half-life requires daily dosing but may result in slightly less sustained receptor occupancy between doses. Energy expenditure may increase modestly through enhanced fat oxidation.
Research Summary
Weight Management (SCALE Program)
Strong EvidenceSCALE Obesity and Pre-Diabetes (n=3731): 3.0 mg liraglutide produced 8.0% weight loss vs 2.6% placebo at 56 weeks; 63% achieved >5% loss vs 27% placebo. SCALE Diabetes: 6.0% weight loss. SCALE Maintenance: subjects regaining after initial diet lost an additional 6.1% vs 0.2% placebo on liraglutide.
Cardiovascular Outcomes (LEADER)
Strong EvidenceLEADER trial (n=9340, high CV risk T2D): 13% reduction in 3-point MACE, 22% reduction in CV death, 15% reduction in all-cause mortality vs placebo over 3.8 years. This was the first GLP-1 outcomes trial to demonstrate cardiovascular mortality reduction, establishing the class benefit.
Pediatric Obesity
ApprovedFDA approved liraglutide 3.0 mg for adolescents aged 12+ with obesity in 2020, the first GLP-1 agonist approval in pediatric obesity. SCALE Teens trial showed 7.4 BMI unit reduction vs 1.6 for placebo.
Calculate your Liraglutide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Weight management | 0.6 mg/day x1 week, then 1.2 mg x1w, 1.8 mg x1w, 2.4 mg x1w, 3.0 mg maintenance | Daily | Subcutaneous |
| Type 2 diabetes | 0.6 mg/day for 1 week, increase to 1.2 mg; max 1.8 mg/day | Daily | Subcutaneous |
Inject at any time of day, with or without meals. Consistent daily timing preferred for stable levels.
Interactions
Safety Profile
Common: nausea (28%), diarrhea (17%), vomiting (11%), decreased appetite, headache. GI effects generally improve over 4-8 weeks. Serious: pancreatitis (rare; discontinue if suspected), gallbladder disease, increased heart rate (+2-3 bpm), thyroid C-cell tumor risk (rodent data). Contraindicated in personal/family history of MTC or MEN2 syndrome. Risk of hypoglycemia low as monotherapy but increases with sulfonylureas/insulin.
References
- [1]Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22.
- [2]Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.
- [3]Kelly AS, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117-2128.